ADC PAYLOADS - Progress in Development of Camptothecin-Based ADC Therapeutics
Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, say the recent progress in research on novel camptothecin payloads highlights the potential for developing a new generation of ADCs that can overcome some of the limitations of first-generation therapies.
SPECIAL FEATURE - Bioavailability & Solubility: The Promise of Novel Ingredients
Contributor Cindy H. Dubin, speaks with several innovating companies to discuss the use of novel excipients as well as other methods and technologies for tackling bioavailability and solubility once and for all.
FORMULATION FORUM - Lymphatic versus Portal Drug Delivery: An Understanding of Drug Oral Absorption & Food Effect
Jim Huang, PhD, and Shaukat Ali, PhD, say the lymphatic system is a distinctive route that is essential for drug transport and delivery of large and lipophilic molecules by alleviating the challenges in penetrating blood capillaries.
TREND SCOUTING - Anticipating the Future of Pharma
Gregor Deutschle says by implementing a strategic, considerate, and proactive approach to trend forecasting, pharmaceutical service providers can effectively weigh the benefits and challenges of potential trends, invest in those most aligned with customer needs, and avoid the allocation of time and resources in trends that will not provide meaningful ROI.
ECO-DESIGN TOOL - How Life Cycle Assessment is Transforming Drug Delivery Device Sustainability
Alex Fong, MBA, believes in an era where sustainability is not just a goal but a necessity, LCA has the potential to reshape how the pharmaceutical industry approaches this multifaceted issue.
DRUG DEVELOPMENT - Improving Bioavailability & Solubility in OSDs
Hibreniguss Terefe, PhD, explores the options available to improve bioavailability and solubility and provides guidance to support decision-making when designing oral formulations for poorly soluble drug candidates in early development.
CELL-FREE GENE SYNTHESIS - Eliminating Critical Bottlenecks in Genetic Medicine Development
Marc Unger explores the market trends, challenges, and opportunities new DNA production technologies provide to accelerate genetic advances in healthcare.
EXECUTIVE INTERVIEW - Lonza: Driving Innovation & Sustainability: CDMO Trends & the Future of ADCs
Sebastian Stenderup, Executive Director, Head of Commercial EMEA, Lonza, discusses some of the trends CDMOs are currently facing, from the growth of ADCs to the importance of sustainability, and how his company is responding to them.
CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials
Neil Vivian, MSc, says advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.
EXECUTIVE INTERVIEW - How Vetter’s Expansion of its Senior Management Team Aligns With Prioritization of Strategic Growth
Vetter’s leadership discusses the company’s vision for strategic restructuring, their insights on Contract Development and Manufacturing trends in 2025, and what this strategic change means for the sustainable growth of the company and its global expansion.
ORAL DOSAGE FORMS - The Future of Oral Dosage: Innovations, Challenges & the Path Forward in 2025
Sébastien Croquet explores the latest industry challenges, cutting-edge manufacturing techniques, and patient needs defining today’s oral delivery methods, and breaks down some of the ways drug producers can ride, or even define, the next wave of oral drug delivery.
RUV CLOSURES - Daikyo PLASCAP® RUV Closures: Securing Annex 1 Compliance Through Contamination-Controlled Closure Innovation
Jim Thompson, MBA, explains how through a long-standing partnership with Daikyo, West can answer multi-faceted vial stoppering and capping challenges with both Crystal Zenith® (CZ) polymer nested vials and PLASCAP® Ready-to-Use Validated (RUV) press-fit closures.
SPECIAL FEATURE - Analytical Testing – Diverse Demands & Therapies Require Diverse Analyses
Contributor Cindy H. Dubin highlights how analytical testing has evolved to address diverse pharmaceutical therapeutics in research and development.
LEADERSHIP PANEL - What Will Have the Most Impact on Drug Development in 2025?
Contributor Cindy H. Dubin asked several life science leaders what they believe will have the greatest impact on drug development in 2025.
FORMULATION FORUM - Nanoparticle Technologies for Oral Delivery of Peptides & Proteins
Jim Huang, PhD, and Shaukat Ali, PhD, examine various nanoparticle technologies in oral delivery of large molecules.
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
How to Choose the Right CDMO for Your Pharmaceutical Project
This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.
Understanding the Foundation of LNP Formulation Success
Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….
Lyophilization Development: Quality by Design Approach
Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……
Choosing the Right Particle for Your Nanomedicine Application
Nanoparticles are revolutionizing the landscape of nanomedicine, enabling significant advancements in early detection, targeted drug delivery, disease monitoring, and imaging. Due to their nanoscale size, these particles….
Join us for the inaugural Quotient Sciences Capability Expo, hosted at our state-of-the-art Garnet Valley facility.
This unique event offers a behind-the-scenes look at how we support molecules from preclinical stages through to commercial manufacturing…..
Have expert content to share? Contact us
EXCLUSIVE WHITEPAPERS
WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations
By overcoming key challenges 3D screen printing is unlocking new possibilities in drug development and manufacturing.
WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide
Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug…
CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form
In this CPHI Award-winning case study, learn how Adare scientists took the alternative sprinkle version out of the lab and into the hands of patients.
ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products
Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs.
WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers
This whitepaper explores the various types of technology transfer from preclinical to commercial stages and successful strategies to foster innovation.
EXCLUSIVE WEBINARS
WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
WEBINAR - ABISOL Emulsion Preconcentrate Kit & ABISORB-DC Excipient System for Tableting Lipids
ABITEC Technical Business Director, John Tillotson, RPh, PhD, discusses ABITEC’s latest products: The ABISOL Emulsion Preconcentrate kit for the easy formulation of emulsified drug delivery systems and the….
WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond
Join Quotient Sciences’ experts on July 18 as we explore the latest developments in orally-delivered GLP-1 agonists, the potential for these therapeutics and overcoming the manufacturing challenges.
MARKET NEWS & TRENDS
SGS Designated as a Notified Body Under EU IVDR
SGS, the world’s leading testing, inspection and certification company, is delighted to announce the designation of SGS Belgium NV as a Notified Body (NB) under…
PCI Pharma Services to Acquire US-Based Aseptic Fill-Finish CDMO Ajinomoto Althea
PCI Pharma Services is acquiring an entire equity stake in Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co.,…
Stefan Seuferling Takes Over Management of the Gerresheimer Medical Systems Business Unit
Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, has arranged the management succession for its…
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients With Cyclin E1+ PROC
Zentalis Pharmaceuticals, Inc. recently announced the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in…
Purple Biotech Reports Positive NT219 Data for Colorectal & Head & Neck Cancers
Purple Biotech Ltd. recently announced two posters reporting new NT219 data presented at the American Association for Cancer Research (AACR 2025) Annual Meeting on Sunday…
Artelo Biosciences Announces New Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
Artelo Biosciences, Inc. recently announced new research published in the peer-reviewed Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro and in vivo…
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA From Pretargeted RIT Platform
Y-mAbs Therapeutics, Inc. recently announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of…
Polyrizon Reports Successful Safety Study of a Formulation of Allergy Blocker in Human Nasal Tissue Model
Polyrizon Ltd. recently announced the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product’s development…
Avidicure Launches With $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer
Avidicure recently announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM,…
BriaCell Confirms 100% Resolution of Lung Metastasis With Bria-OTS
BriaCell Therapeutics Corp. confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months after initial treatment in the ongoing…
Inmagene Reports Topline Results From Phase 2a Study of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life in Patients With Alopecia Areata
Inmagene Biopharmaceuticals recently reports topline results from the Phase 2a trial of IMG-007 in patients with severe alopecia areata (AA). “AA is an I&I disease…
Facility Update From Sever Pharma Solutions
In 2024, our Putnam site fully commissioned and qualified two new High Potent API processing suites, one for development and one for GMP manufacturing. These…
Cytovation Raises $6M to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts
Cytovation ASA recently announced it has raised NOK62 million (US$6m) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101…
Boehringer Ingelheim & Tessellate Bio Partner to Develop First-in-Class Precision Treatments for People With Hard-to-Treat Cancers
Boehringer Ingelheim and Tessellate Bio have entered into a research collaboration and global license agreement. Jointly the partners will focus on the development of first-in-class,…
BPGbio Presents New Research on Tumor Metabolism, Immunotherapy & Diagnostics
BPGbio, Inc. recently announced the presentation of seven presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in…
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences, Ltd. recently announced dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients…
Beghou Consulting Prepares for Next Phase of Growth, Names Chief Services Officer to Succeed Founder & CEO
Beghou Consulting, a leading provider of data, analytics, and technology solutions for life sciences commercialization, recently announced Adrienne Lovink, Chief Services Officer, will assume the…
Bluejay Therapeutics Announces Upcoming Presentation of Preclinical Data in Metabolic Dysfunction-Associated Steatohepatitis
Bluejay Therapeutics recently announced it will present new preclinical data on the characterization of BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor being investigated for the…
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of First-in-Class Oral STAT6 Degrader
Kymera Therapeutics, Inc. recently announced it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of…
March Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma
March Biosciences recently announced the first patient has been dosed in its Phase 2 clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for…
